These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8484262)

  • 1. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
    Narita M; Nagai E; Hagiwara H; Aburada M; Yokoi T; Kamataki T
    Xenobiotica; 1993 Jan; 23(1):5-10. PubMed ID: 8484262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.
    Yokoi T; Narita M; Nagai E; Hagiwara H; Aburada M; Kamataki T
    Jpn J Cancer Res; 1995 Oct; 86(10):985-9. PubMed ID: 7493919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
    Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
    Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
    Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
    Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
    Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
    Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
    Rivory LP; Robert J
    Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
    Prijovich ZM; Chen KC; Roffler SR
    Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.
    Kodawara T; Higashi T; Negoro Y; Kamitani Y; Igarashi T; Watanabe K; Tsukamoto H; Yano R; Masada M; Iwasaki H; Nakamura T
    Basic Clin Pharmacol Toxicol; 2016 May; 118(5):333-7. PubMed ID: 26518357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
    Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
    Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
    Charasson V; Haaz MC; Robert J
    Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
    Angenault S; Thirot S; Schmidt F; Monneret C; Pfeiffer B; Renard P
    Bioorg Med Chem Lett; 2003 Mar; 13(5):947-50. PubMed ID: 12617927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
    Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
    Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
    Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
    J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
    Rivory LP; Bowles MR; Robert J; Pond SM
    Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
    Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
    Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of green tea compounds on irinotecan metabolism.
    Mirkov S; Komoroski BJ; Ramírez J; Graber AY; Ratain MJ; Strom SC; Innocenti F
    Drug Metab Dispos; 2007 Feb; 35(2):228-33. PubMed ID: 17108060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of CPT-11. Impact on activity.
    Rivory LP
    Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
    Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
    PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
    Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
    J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.